All publications listed are from December 2021.
1. Ding Q, Qin L, Wojeck B, Inzucchi SE, Ibrahim A, Bravata DM, Strohl KP, Yaggi HK, Zinchuk AV. Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study. Annals Of The American Thoracic Society 2021, 18(12): 2067-2078. doi: 10.1513/AnnalsATS.202012-1556OC. PMID: 34185617. PMCID: PMC8641817.
2. Sangha V, Lipska K, Lin Z, Inzucchi SE, McGuire DK, Krumholz HM, Khera R. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circulation. Cardiovascular Quality And Outcomes 2021, 14(12): e008381. doi: 10.1161/CIRCOUTCOMES.121.008381. PMID: 34779654.
3. Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, Martin JS, Carpenter TO. Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing. Journal Of Bone And Mineral Research : The Official Journal Of The American Society For Bone And Mineral Research 2021, 36(12): 2455-2456. doi: 10.1002/jbmr.4317. PMID: 34030212.
4. Brito JP, Ross JS, Deng Y, Sangaralingham L, Graham DJ, Qiang Y, Wang Z, Yao X, Zhao L, Smallridge RC, Bernet V, Shah ND, Lipska KJ. Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. Endocrine 2021, 74(3): 592-602. doi: 10.1007/s12020-021-02779-x. PMID: 34089480.
5. Lee SM, Esserman D, Cheung K, Dziura J, Peduzzi P, Sobieszczyk M. What do we do with our under-enrolled single-center COVID-19 clinical trials? Clinical Trials (London, England) 2021, 18(6): 741-742. doi: 10.1177/17407745211027246. PMID: 34218683. PMCID: PMC8595488.
6. Vaduganathan M, Inzucchi SE, Sattar N, Fitchett DH, Ofstad AP, Brueckmann M, George JT, Verma S, Mattheus M, Wanner C, Zinman B, Butler J. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. Diabetes, Obesity & Metabolism 2021, 23(12): 2775-2784. doi: 10.1111/dom.14535. PMID: 34463409.
7. Sims EK, Cuthbertson D, Herold KC, Sosenko JM. The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes. Diabetes 2021, 70(12): 2922-2931. doi: 10.2337/db21-0519. PMID: 34551936. PMCID: PMC8660991.
8. Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, Ohneberg K, Ofstad AP, Salsali A, George JT, Hantel S, Bluhmki E, Lachin JM, Zannad F. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Failure 2021, 8(6): 4517-4527. doi: 10.1002/ehf2.13615. PMID: 34605192.
9. Tarabra E, Nouws J, Vash-Margita A, Hellerstein M, Shabanova V, McCollum S, Pierpont B, Zhao D, Shulman GI, Caprio S. CIDEA expression in SAT from adolescent girls with obesity and unfavorable patterns of abdominal fat distribution. Obesity (Silver Spring, Md.) 2021, 29(12): 2068-2080. doi: 10.1002/oby.23295. PMID: 34672413. PMCID: PMC8612981.
10. Butt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, Kosiborod MN, Maria Langkilde A, Lindholm D, Martinez FA, Bengtsson O, Schou M, O'Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV, Køber L. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation. Heart Failure 2021, 14(12): e008837. doi: 10.1161/CIRCHEARTFAILURE.121.008837. PMID: 34802253.
11. Wong AH, Ray JM, Cramer LD, Brashear TK, Eixenberger C, McVaney C, Haggan J, Sevilla M, Costa DS, Parwani V, Ulrich A, Dziura JD, Bernstein SL, Venkatesh AK. Design and Implementation of an Agitation Code Response Team in the Emergency Department. Annals Of Emergency Medicine 2021 doi: 10.1016/j.annemergmed.2021.10.013. PMID: 34863528.
12. Bhat N, Narayanan A, Fathzadeh M, Kahn M, Zhang D, Goedeke L, Neogi A, Cardone RL, Kibbey RG, Fernandez-Hernando C, Ginsberg HN, Jain D, Shulman G, Mani A. Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. The Journal Of Clinical Investigation 2021 doi: 10.1172/JCI153724. PMID: 34855620.
13. Chouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, Mori M, Clark KA, Miller PE, Fuery MA, Rogers JG, Notarianni A, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T, Mullan CW. Impact of Obesity on Heart Transplantation Outcomes. Journal Of The American Heart Association 2021, 10(23): e021346. doi: 10.1161/JAHA.121.021346. PMID: 34854316.
Yale’s Section of Endocrinology & Metabolism works to improve the health of individuals with endocrine and metabolic diseases by advancing scientific knowledge; applying new information to patient care; and training the next generation of physicians and scientists to become leaders in the field. To learn more about their work, visit Endocrinology & Metabolism.